Acetogenic fermentation of carbon monoxide gas

By incrementally increasing CO concentrations in growth cycles without yeast extracts, the method conditions acetogens to tolerate 100% CO, overcoming growth inhibition and enhancing industrial viability and efficiency in CO-rich gas fermentation.

WO2024228166A1PCT designated stage expired Publication Date: 2024-11-07CIRCE BIOTECHNOLOGIE GMBH +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2024/054315
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-03
Filing Date
2024-05-03
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Acetogens, such as Thermoanaerobacter kivui, face growth inhibition due to high carbon monoxide (CO) concentrations, limiting their industrial application in treating CO-rich gases, and existing methods for conditioning them require expensive yeast extracts and vitamins.

Method used

A method involving incremental CO concentration increases in successive growth cycles without yeast extract or vitamins, leading to genetically modified acetogens capable of utilizing 100% CO as a sole carbon source, enhancing growth rates and industrial viability.

Benefits of technology

Conditioned acetogens exhibit higher growth rates and CO tolerance, enabling efficient acetogenic fermentation of CO-rich gases without costly additives, thus improving industrial applicability and economic feasibility.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IB2024054315_07112024_PF_FP_ABST
    Figure IB2024054315_07112024_PF_FP_ABST
Patent Text Reader

Abstract

This invention relates to acetogenic gas fermentation, specifically of carbon monoxide (CO) gas and gas mixtures containing the same, typically comprised in synthesis gas or industrial waste gasses in fluctuating quantities, using acetogens (acetogenic bacteria), such as Thermoanaerobacter kivui (T. kivui). The invention finds particular application in industrial fermentation of the gaseous C1 substrates CO and CO2, as well as H2 and any mixture thereof, in bioreactors.
Need to check novelty before this filing date? Find Prior Art

Description

ACETOGENIC FERMENTATION OF CARBON MONOXIDE GAS

[0001] FIELD OF THE INVENTION

[0002] THIS INVENTION relates to acetogenic gas fermentation, specifically of carbon monoxide (CO) gas and gas mixtures containing the same, typically comprised in synthesis gas or industrial waste gasses in fluctuating quantities, using acetogens (acetogenic bacteria), such as Thermoanaerobacter kivui (T. kivui). The invention finds particular application in industrial fermentation of the gaseous C1 substrates CO and CO2, as well as H2and any mixture thereof, in bioreactors.

[0003] The invention provides a method of conditioning acetogens, such as T. kivui, for acetogenic fermentation of CO-containing gases such as biomass gasification, waste gasification, blast furnace gas and other industrial waste gasses containing fluctuating quantities of CO, so that they are able to utilize non-constant gas streams with high CO content next to CO2 and H2. The invention extends to conditioned acetogens, such as T. kivui, produced by performing the method. The invention also provides conditioned strains of acetogens, such as T. kivui, optionally for use in performing acetogenic fermentation of CO gas. The invention further provides a method of acetogenic fermentation of CO gas. The invention also provides for use of conditioned strains of acetogens, such as T. kivui, in performing acetogenic fermentation of CO gas.

[0004] BACKGROUND TO THE INVENTION

[0005] ACETOGENESIS is, generally speaking, a process through which microorganisms, known as acetogens, convert carbon dioxide (CO2) or carbon monoxide (CO) into acetate along the Wood-Ljungdahl pathway, typically via acetyl-CoA.

[0006] Along this pathway, in the case of CO, the CO is first oxidised to CO2by a CO dehydrogenase in a biological water-gas shift reaction. The CO2 is then fixed into a methyl group and fused with another molecule of enzyme-bound CO to acetyl-CoA by the action of a bifunctional CO dehydrogenase / acetyl-CoA synthetase. CO can serve as sole carbon and energy source, while CO2 as carbon source requires H2 for energy provision.

[0007] The acetogenic ability of acetogens finds useful application in the treatment of gases containing CO2and / or CO, such as syngas (synthesis gas) or industrial waste gasses, such as blast furnace gas or flue gasses from combustion and incineration processes), to produce useful products, such as acetic acid and ethanol, from such gases. This process is known as acetogenic gas fermentation.

[0008] Acetogens are naturally capable of metabolising CO along the Wood- Ljungdahl pathway (or reductive acetyl-CoA pathway) for autotrophic growth and to produce acetyl-CoA. However, such growth is often inhibited by the presence of high CO concentrations because of CO toxicity. This limits the biosynthetic potential of acetogens in industrial applications. Industrial applications can have gasses with high CO content, and that CO content can also fluctuate over time, e.g. in the case of non-constant feedstock (biomass, waste) and / or throughput fluctuations.

[0009] The challenge presented by CO toxicity in exploiting acetogens in treating high CO concentration gases has received attention from inventors in the past, includingby conditioning acetogens for CO metabolization through processes such as adaptive laboratory evolution (ALE) (see e.g. V. G. Debabov Modern, “Approaches to the Creation of Industrial Microorganism Strains”, Russian Journal of Genetics Vol.51 No.42015 and Claudio J. R. Frazao and Thomas Walther, “Syngas and Methanol-Based Biorefinery Concepts”, Chem. Ing. Tech.2020, 92, No.11, 1680–1699.

[0010] In the applicant’s experience, while there has been moderate success in conditioning acetogens for CO metabolization, there is an unanswered need to do so in a manner that achieves microorganism growth rates that may be industrially commercially attractive (e.g. higher growth rates to make the microbial catalyst more economic). A further unanswered need is to condition acetogens for CO metabolization in the absence of expensive yeast extracts, vitamins and other costly additives. Such a yeast extract- containing medium is referred to as “complex medium” or “undefined medium” in the context of this invention, in contrast to a chemically defined medium free of yeast and nutrients.

[0011] T. kivui is one thermophilic, anaerobic acetogen known to exhibit autotrophic growth using CO2 / hydrogen (H2) as carbon and energy substrates. T. kivui was originally understood not to grow autotrophically in a high concentration CO or, more specifically, 100% substrate, but was subsequently found to be susceptible to conditioning that enables CO metabolization and autotrophic growth in a high CO concentration substrate, or even in a 100% CO substrate, however, this is at unattractively low growth rates in both chemically defined media and complex media.

[0012] The present invention finds application improving the growth rate of acetogens, such as T. kivui, in high CO concentration substrates and, in particular, in a 100% CO substrate.

[0013] SUMMARY OF THE INVENTION

[0014] ACCORDING TO A FIRST, BROAD, ASPECT OF THE INVENTION, THERE IS PROVIDED a method of conditioning a culture of acetogens for acetogenic fermentation of carbon monoxide (CO) gas to be fermented (i.e. CO feed gas), the method including growing a culture of unconditioned acetogens in a fermentation medium devoid of yeast extract and vitamins for at least three consecutive growth cycles on CO gas (i.e. CO treatment gas), distinct of CO feed gas) as a main or sole carbon source, wherein the concentration of CO in the CO treatment gas is incrementally increased over the three growth cycles. Thus, the concentration of CO in the CO treatment gas is increased in a stepwise fashion over the consecutive growth cycles.

[0015] As used herein, reference to “main or sole carbon source” should be understood to mean that, on a molar basis, at least 50% of the biomass growth of the culture of acetogens and / or of the production of fermentation product, referenced herein, by the culture of acetogens, originates from metabolization of CO.

[0016] A culture of acetogens thus conditioned may comprise or consist of a proliferated culture of acetogens selected from the culture of acetogens that was subjected to conditioning wherein the proliferated selected culture of acetogens comprises at least one genetic modification compared to the culture of acetogens that was subjected toconditioning (i.e. the culture of acetogens prior to the method of conditioning), which genetic modification results from the conditioning.

[0017] Alternatively, or in addition, a culture of acetogens thus conditioned may comprise a proliferated culture of mutated acetogens that include at least one genetic modification compared to the culture of acetogens that was subjected to conditioning (i.e. the culture of acetogens prior to the method of conditioning), which genetic modification results from the conditioning.

[0018] The conditioned acetogens thus produced may be able to grow on CO feed gas, more specifically high concentration CO feed gas, and most particularly 100% CO feed gas, as sole or main carbon source.

[0019] The acetogens that are subjected to conditioning and the conditioned acetogens may in particular be selected from T. kivui and variants thereof, but the invention extends to any acetogens, in particular being any thermophilic acetogens, that are subjected to the method of conditioning, and any conditioned acetogens thus produced. Most desirably, thermophilic acetogens to which the invention extends are those that have growth traits, optimum and / or robust growing conditions and other growth characteristics approximating that of T. kivui. These may include a growth optimum at a temperature of 55-70°C.

[0020] Both the conditioning method characterised herein, and the method of fermenting CO feed gas characterised herein may, in respect of the growth of the acetogens, draw benefit from the sensible heat of CO gas, whether as CO feed gas or as CO treatment gas. In other words, the feed gas or treatment gas, as the case may be,may supply at least some heat required for achieving an optimum growth temperature for the acetogens that are being subjected to conditioning or the conditioned acetogens.

[0021] THE FIRST BROAD ASPECT OF THE INVENTION EXTENDS to using the conditioned acetogens thus obtained in a method to ferment a CO feed gas and produce a fermentation product, which is further characterised in more detail with reference to the fourth aspect of the invention, below. The method may form part of a CO feed gas fermentation process comprising upstream and downstream operations in addition to the method, as characterised in more detail herein.

[0022] The fermentation product may be in solid, liquid or gaseous form. In a preferred embodiment, it is a liquid or gaseous alcohol or acid, mono- or divalent.

[0023] The CO feed gas may be any CO containing gas, including industrial CO containing gases, for example an industrial waste gas containing CO or a synthesis gas (e.g. produced in a gasification process of e.g. biomass or waste).

[0024] The fermentation product may, primarily, comprise acetic acid, but the invention extends the meaning of “fermentation product” to downstream products produced by the fermentation of the CO feed gas or by further processing of products directly produced by the fermentation, for example including mono- or divalent alcohols or lactic acid and / or further or other products as more comprehensively characterised below.

[0025] Performing the method may comprise the use of a reactor. In other words, the method may be performed using a reactor. Such a reactor may, for example, beselected from an industrial-scale fermenter or stirred tank, airlift reactor, bubble column reactor, or loop (plug flow) reactor.

[0026] The gas fermentation method may be performed continuously, i.e. as part of a continuous process. Such continuous performance of the method may comprise continuously providing fresh CO feed gas to conditioned acetogens that are used for fermentation, while continuously recovering fermentation product produced (in a preferred embodiment extracellularly) by the conditioned acetogens.

[0027] Continuously recovering fermentation product produced by the conditioned acetogens may include continuously extracting or separating fermentation product from the fermentation medium. Such extraction or separation may, for example, include using membrane processes, vaporization, or solvent extraction, typically in situ.

[0028] In the context of a continuous process that includes performing the method using a reactor, such a process may therefore include feeding fresh CO feed gas into the reactor and continuously recovering fermentation product produced inside the reactor.

[0029] Such continuous recovery may either be performed in situ inside the reactor or may include withdrawing fermentation product rich fermentation medium from the reactor, recovering fermentation product from the fermentation product rich fermentation medium to produce recovered fermentation product and fermentation product lean, or free, fermentation medium, and continuously recycling the fermentation product lean, or free, fermentation medium to the reactor.

[0030] The method may be performed to remove all CO from the CO feed gas that is subjected to fermentation. Hence the application of the invention can be to obtain a target product, but also to biologically purify a gas stream, e.g. an exhaust gas.

[0031] The method, and therefore a process implementing the method, may include performing aerobic gas fermentation to ferment other carbon sources, such as methane, which may be present in the feed gas.

[0032] MORE SPECIFICALLY, ACCORDING TO THE FIRST ASPECT OF THE INVENTION, THERE IS PROVIDED a method of conditioning a culture of acetogens, such as Thermoanaerobacter kivui (T. kivui), for acetogenic fermentation of carbon monoxide (CO) gas (i.e. CO feed gas), the method including – successively growing the culture of acetogens on CO gas (CO treatment gas) of which the concentration of CO is progressively increased in respective growing cycles (i.e. using respective successive gaseous substrates of CO treatment gas of increased CO concentration), wherein the concentrations of CO in the CO treatment gases are incrementally increased from about 30% v / v to 100% v / v (“CO growth step”), thereby producing a culture of conditioned acetogens for acetogenic fermentation of CO feed gas.

[0033] The method may include a prior step of growing the culture of acetogens for at least one growth cycle on (i.e. using a gaseous substrate of) high CO synthesis gas (“syngas”) (“syngas growth step”).

[0034] The method may also include a prior step of growing the culture of acetogens for at least one growth cycle on (i.e. using a gaseous substrate comprising) a hydrogen (H2) and carbon dioxide (CO2) gas that is substantially free of CO (“CO free growth step”).

[0035] Preferably, the method comprises successively performing the CO free growth step, first (“first growing stage”), the syngas growth step, second (“second growing stage”), and the CO growth step, third (“third growing stage”).

[0036] The first performed of the growth steps may be performed on CO free gas, and the growth step may be performed using an unconditioned culture of the acetogens. Thus, when the CO free growth step is the first growing stage, then the CO free growth step may be performed on an unconditioned culture of the acetogens.

[0037] In this specification, the term “growth cycle” means a single division cycle to form one new generation of each acetogen, such as T. kivui, from a preceding generation, such that in one growth cycle a single cell gives rise to two cells, so as to double the cell population of acetogens. Such a “growth cycle” may otherwise be understood as a “passage” of a culture, comprising several generations of exponential growth.

[0038] Furthermore, in this specification, the term “CO gas” means any gas that comprises or consists of CO, thus including 100% v / v CO and gas comprising lower concentrations of CO, except where it is expressly indicated in the text that 100% v / v CO or gas comprising a lower concentration of CO is used, in which case the term has a corresponding, more limited, meaning. Within this meaning, CO gases to which the invention finds application, specifically in respect of metabolization of CO, includes synthesis gas and industrial waste gasses that comprise CO in fluctuating quantities. Thus,“CO gas” includes CO-containing gases such as synthesis gas produced by, for example, biomass gasification or waste gasification, and also blast furnace gas and other industrial waste gasses containing fluctuating quantities of CO. In this context, it is understood that the invention finds industrial application to metabolise CO in non-constant composition gas streams with high CO content, typically in combination with CO2and H2.

[0039] Also, in this specification the meaning of the term “acetogen” includes any mesophilic or thermophilic bacteria, such as T. kivui, capable of generating acetate as an end product of anaerobic fermentation of carbon dioxide gas, typically in the presence of hydrogen gas.

[0040] The temperature range of the medium in which such mesophilic and thermophilic bacteria is used for fermentation may be 15 to 44°C, more specifically 15 to 37°C, and 37 to 85°C, more specifically 45 to 85°C, respectively. Thermophilic bacteria are preferred, because they can utilize the sensible heat in the feed gas, e.g. when it comes from a thermal process.

[0041] It would be known to those of skill in the art in the invention that acetogenic bacteria (i.e. acetogens) are a diverse group of bacteria that are capable of producing acetate as a metabolic end product. The present invention finds particular application in respect of thermophilic bacteria (i.e. thermophilic acetogens). Some examples of such thermophilic acetogenic bacteria to which this invention applies (i.e. which may be conditioned according to the method of the invention of conditioning an acetogen for metabolization of CO) include – Moorella thermoacetica DSM 521; Moorella thermoacetica ATCC 39073; Moorella thermoacetica ATCC 49707;Moorella thermoacetica DSM 6867; Moorella thermoacetica ATCC 31490; Moorella thermoacetica ATCC 35608; Moorella thermoacetica DSM 2955; Moorella thermoacetica DSM 12993; Moorella thermoacetica DSM 12797; Moorella thermoacetica DSM 11768; Moorella thermoacetica ATCC 33924; Moorella thermoacetica DSM 103132; Moorella thermoacetica DSM 103284; Moorella thermoacetica DSM 21394; Moorella thermoacetica Y72; Moorella thermoautotrophica DSM 7417; Moorella glyerini DSM 11254 Moorella stamsii DSM 26217 Moorella perchloratireducens An10 Moorella mulderi DSM 14980 Moorella humiferrea DSM 23265 Thermoanaerobacter kivui LKT-1 DSM 2030 Thermoacetogenium phaeum DSM 12270.

[0042] Persons skilled in the art of the invention would further appreciate that acetogenic bacteria are named after their ability to produce acetate, which is their primary metabolic end product. Acetate is a versatile chemical that has numerous industrial and commercial applications, such as in the production of solvents, plastics, and food additives.

[0043] There are several other products that may be produced from acetate, whether through continued fermentation or further procession, to which the present invention extends in terms of fermentation products. Such products and may include – monovalent alcohols: ethanol; n-propanol; isopropanol; n-butanol; 2-butanol; isobutanol; pentanol; hexanol; heptanol; octanol; divalent alcohols: ethylene glycol; propylene glycol; 1,4-butanediol; 2,3-butanediol; 1,3-butanediol; pentanediol; hexanediol; octanediol; monovalent acids: acetic acid; lactic acid;glycolic acid; propionic acid; butyric acid; iso-butyric acid; valeric acid; iso-valeric acid; caproic acid; hexanoic acid; divalent acids: succinic acid; malic acid; fumaric acid; and tartaric acid.

[0044] Other compounds that acetogens can make, and that are included within the scope of fermentation products, include acetone, hydrogen, carbohydrates, proteins and hydrocarbons.

[0045] The fermentation products may be produced as intracellular or extracellular products, and may be gaseous, liquid or solid.

[0046] In a preferred embodiment of the invention, the fermentation products are produced as extracellular products. Optically pure products in case of enantiomers are preferred.

[0047] The fermentation products may be useful as chemical building blocks, feed, food or fuels.

[0048] “Unconditioned” in the sense used herein means unselected or unmutated with respect to the genetic modifications imparted to the proliferated selected or mutated conditioned acetogens by performing the conditioning method of the invention and embodied by the proliferated selected or mutated acetogens of the invention. Where reference is made to an “unconditioned” acetogen, such reference may therefore include acetogens having mutations resulting from other treatments than that of the conditioning method of the invention. Genetically engineered microorganisms are also included within the meaning of “unmutated” and such microorganisms may therefore also be subjected to conditioning in accordance with the conditioning method of the invention. Post- conditioning genetic engineering is also not excluded.

[0049] The (unconditioned) acetogen culture that is subject to conditioning may be a wildtype acetogen culture.

[0050] The acetogen culture may, in particular, be T. kivui. In such a case, the T. kivui that is subjected to conditioning according to the method of the first aspect of the invention may be T. kivui LKT-1, more specifically DSM 2030 (ATCC 33488).

[0051] The first growing stage may, more preferably, comprise at least three successive growth cycles, wherein a fresh gaseous substrate of H2 and CO2 gas is provided after the conclusion of each growth cycle.

[0052] The second growing stage may, more preferably, comprise at least two successive growth cycles, wherein a fresh gaseous substrate of high CO syngas is provided after each growth cycle.

[0053] The third growing stage may, more preferably, comprise successively growing the culture of acetogens, e.g. T. kivui, from the second growing stage for at least one growth cycle on each of five CO treatment gases of increasing CO concentrations respectively (i.e. using respective successive gaseous substrates of CO treatment gas), wherein the concentrations of CO in the respective CO treatment gases (i.e. in the successive gaseous substrates of CO treatment gas) are selected from, or more preferably are, 30% v / v, 40% v / v, 50% v / v, 60% v / v and 100% v / v respectively.

[0054] In the third growing stage, a fresh (i.e. a gaseous substrate of) CO treatment gas may be provided after each growth cycle.

[0055] Each growth cycle may comprise culturing the acetogens in fresh growth medium (i.e. fermentation medium). Therefore, the method may include transferring the acetogens from spent growth medium used in an earlier growth cycle to fresh growth medium to be used in a subsequent growth cycle.

[0056] The high CO syngas may be syngas that comprises a major proportion, by volume, of CO gas. Thus, the high CO syngas may comprise more CO than any other gas, by volume.

[0057] For example, the high CO syngas may comprise 50% v / v or more CO. In one embodiment of the invention, the high CO syngas may comprise about 52% v / v CO. Typically, in addition to CO, the high CO syngas may comprise H2and CO2.

[0058] The first, second, and third growing stages may each comprise culturing the acetogens in a liquid growth medium (i.e. fermentation medium). For example, the liquid growth medium may be a synthetic serum medium.

[0059] The first, second, and third growth stages, and therefore the growth cycles thereof, may comprise culturing the acetogens in a chemically defined minimal growth medium (i.e. fermentation medium), i.e. a growth medium that excludes growth stimulants, and in particular excludes vitamins, complex nutrients, yeast extract, and / or peptone.

[0060] The method may also include isolating and characterising a conditioned acetogen from the third growing stage.

[0061] An isolated conditioned acetogen may have at least one genetic modification to its genome relative to an unconditioned acetogen, where such genetic modification may be one or more insertion, including a duplication such as a transposable element-induced duplication. The isolated and characterised acetogen may have at least one transposon in its genome. The at least one genetic modification may further include any one or more of at least one SNP (single-nucleotide polymorphism) mutation; and / or at least one deletion.

[0062] In the case of the isolated conditioned acetogen being T. kivui, the conditioned T. kivui, may have at least one genetic modification to its genome relative to awildtype T. kivui (DSM 2030), thus being conditioned T. kivui compared to wildtype T. kivui (DSM 2030).

[0063] The genetic modification may, in particular include, but is not limited to, one or more insertions, including one or more duplications such as a transposable element- induced duplication. The isolated T. kivui may have at least one transposon in its genome. In addition to the insertion the genetic modification may include one or more SNP mutations, or at least one deletion, or both one or more SNP mutations and at least one deletion.

[0064] Duplications, including transposable element-induced duplications that may be included may, specifically with reference to the NCBI genome with accession number NZ_CP009170.1, be one or both of – at least one, optionally two, duplications of at least one of regions between 1,841,579 to 1,901,680 and 1,910,027 to 1,935,735; and the region from 1,917,220 to 1,932,727.

[0065] The duplication in the region from 1,917,220 to 1,932,727 may be hydrogen- dependent CO2 reductase (HDCR). Such duplication may be in the region 1,921,445 to 1,922,281, specifically at position 1,921,445.

[0066] The duplication / s in the region of 1,841,579 to 1,901,680 may be one, more preferably both, of electron-bifurcating hydrogenase (EBH) and energy-conserving hydrogenase 2 complex (Ech hydrogenase). Such duplications may be respectively at positions 1,883,375 to 1,887,553 and 1,893,535 to 1,900,304.

[0067] The duplication / s in the region of 1,910,027 to 1,935,735 may be at least one, more preferably all, of acetyl-CoA decarbonylase / synthase complex subunit alpha (ACDS), lpdA, methylene-THF reductase, methylene-THF dehydrogenase, formate tetrahydrofolate ligase, formate / nitrite family transporter protein, hydrogen-dependent CO2 reductase (HDCR), and carbon monoxide dehydrogenase accessory protein CooC. Such duplications may respectively be at positions 1,910,148 to 1,911,086, 1,911,897 to 1,913,282, 1,913,298 to 1,914,839, 1,914,852 to 1,916,379, 1,917,220 to 1,918,899, 1,919,741 to 1,920,616, 1,921,445 to 1,927,301, and 1,934,883 to 1,935,659.

[0068] In particular, the conditioned T. kivui sequence having duplication / s may be conditioned from a clonal strain of T. kivui designated CO-1 having a nucleotide sequence of SEQ ID NO: 8. The nucleotide sequence may have at least 80%, 85%, 90%, 95% or above identity to the nucleotide sequence as set out in SEQ ID NO: 8, or may be a sequence which hybridises under stringent conditions to the reverse complement of the nucleotide sequence as set out in SEQ ID NO: 8.

[0069] The conditioned T. kivui sequence having duplication / s may be from a clonal strain of T. kivui designated CO-1 having further, or alternative, duplication / s and having a nucleotide sequence of SEQ ID NO: 9. The nucleotide sequence may have at least 80%, 85%, 90%, 95% or above identity to the nucleotide sequence as set out in SEQ ID NO: 9, or may be a sequence which hybridises under stringent conditions to the reverse complement of the nucleotide sequence as set out in SEQ ID NO: 9.

[0070] Hybridisation may occur under stringent conditions that include hybridisation in 6x sodium chloride / sodium citrate (SSC) at 40 to 45°C, followed by a wash in 0.1 to 0.2x SSC at about 60°C to about 65 °C.

[0071] The duplication in the region from 1,917,220 to 1,932,727 may arise from conditioning in high CO syngas. One or both of the duplications in the regions from 1,841,579 to 1,901,680 and 1,910,027 to 1,935,735 may arise from conditioning in 100% CO.

[0072] Typically, upon conditioning with 100% CO subsequent to conditioning with high CO syngas, the duplication in the region from 1,917,220 to 1,932,727 may be replaced by one or both of the duplications in the regions from 1,841,579 to 1,901,680 and 1,910,027 to 1,935,735. Therefore, the duplications in the regions between 1,841,579 to 1,901,680 and 1,910,027 to 1,935,735 may exist to the exclusion of the duplication of the region from 1,917,220 to 1,932,727.

[0073] Duplication / s in the region from 1,917,220 to 1,932,727 may have a size of 15,507 bp. Duplication / s in the region from 1,841,579 to 1,901,680 and 1,910,027 to 1,935,735 may have a size / s of 60,101 bp and 25,708 bp respectively, or a single size of 85,809 bp.

[0074] The one or more SNP mutations that may be generated by the method of conditioning may be one or more, typically all, of – cbiQ, cobalt ECF transporter T component; rpoC, DNA-directed RNA polymerase subunit beta’; dapA, 4-hydroxy-tetrahydrodipicolinate synthase; phoU, phosphate signalling complex protein; hypF, carbamoyltransferase; and acsV, corrinoid activation / regeneration protein.

[0075] Even more specifically, the SNP mutations that may be generated, specifically with reference to the NCBI genome with accession number NZ_CP009170.1, may be one or more, typically all, of – cbiQ, cobalt ECF transporter T component at position 341,995; rpoC, DNA-directed RNA polymerase subunit beta’ at positions 1,969,972 and 1,970,146; and dapA, 4-hydroxy-tetrahydrodipicolinate synthase at position 818,980.

[0076] In addition, the SNP mutations that may be generated, specifically with reference to the NCBI genome with accession number NZ_CP009170.1, may be one or more, typically all, of – phoU, phosphate signalling complex protein at position 1,459,688; hypF, carbamoyltransferase, at position 136,300; and acsV, corrinoid activation / regeneration protein, at position 1,903,679.

[0077] In particular, the conditioned T. kivui sequence may be from a clonal strain of T. kivui designated CO-1 comprising a nucleotide sequence of any of, typically all of - cbiQ, cobalt ECF transporter T component as set out in SEQ ID NO: 1; rpoC, DNA-directed RNA polymerase subunit beta’ as set out in SEQ ID NO: 2; and dapA, 4-hydroxy-tetrahydrodipicolinate synthase as set out in SEQ ID NO: 3.

[0078] In addition, the conditioned T. kivui sequence may be from a clonal strain of T. kivui designated CO-1 comprising a further nucleotide sequence of any of, typically all of – phoU, phosphate signalling complex protein as set out in SEQ ID NO: 4; hypF, carbamoyltransferase, as set out in SEQ ID NO: 5; andacsV, corrinoid activation / regeneration protein, as set out in SEQ ID NO: 6.

[0079] The nucleotide sequence may have at least 80%, 85%, 90%, 95% or above identity to the nucleotide sequences as set out in SEQ ID NOs: 1 to 6, or may be a sequence which hybridises under stringent conditions to the reverse complement of the nucleotide sequences as set out in SEQ ID NOs: 1 to 6.

[0080] The deletions that may be generated by the method of conditioning may be full or partial deletions of one or more of – GNAT family N-acetyltransferase; DUF881 domain-containing protein; and hypothetical protein.

[0081] More specifically, the deletions that may be generated, specifically with reference to the NCBI genome with accession number NZ_CP009170.1, may be full or partial deletions of one or more of – GNAT family N-acetyltransferase (partial deletion from position 233,431 to 234,484); DUF881 domain-containing protein (full deletion from position 234,523 to 235,260); and hypothetical protein (partial deletion from position 235,425 to 235,869).

[0082] In particular, the conditioned T. kivui sequence may be from a clonal strain of T. kivui designated CO-1 comprising a nucleotide sequence of SEQ ID NO: 7. The nucleotide sequence may have at least 80%, 85%, 90%, 95% or above identity to the nucleotide sequence as set out in SEQ ID NO: 7, or may be a sequence which hybridisesunder stringent conditions to the reverse complement of the nucleotide sequence as set out in SEQ ID NO: 7.

[0083] In one possible embodiment of the invention, the SNP mutations, the deletions, and the duplications in the genome may include, specifically with reference to the NCBI genome with accession number NZ_CP009170.1, one or more, and more typically all, of – arising from the second growth stage in high CO syngas substrate: SNP mutations of: cbiQ, cobalt ECF transporter T component at position 341,995; rpoC, DNA-directed RNA polymerase subunit beta’ at positions 1,969,972 and 1,970,146; dapA, 4-hydroxy-tetrahydrodipicolinate synthase at position 818,980; duplication of: the region between 1,917,220 and 1,932,727; arising from the third growth stage in 100% CO substrate: SNP mutations of: cbiQ, cobalt ECF transporter T component at position 341,995 (typically remaining from the second growth stage); rpoC, DNA-directed RNA polymerase subunit beta’ at positions 1,969,972 and 1,970,146 (typically remaining from the second growth stage) dapA, 4-hydroxy-tetrahydrodipicolinate synthase at position 818,980 (r typically remaining from the second growth stage); phoU, phosphate signalling complex protein at position 1,459,688. deletions:GNAT family N-acetyltransferase (partial deletion from position 233,431 to 234,484); DUF881 domain-containing protein (full deletion from position 234,523 to 235,260); hypothetical protein (partial deletion from position 235,425 to 235,869); duplication of: regions between 1,841,579 to 1,901,680 and 1,910,027 to 1,935,735 (typically replacing duplication of the region between 1,917,220 and 1,932,727 arising from the second growth stage).

[0084] The method may include cloning the 100% CO population produced by the method and isolating single clones therefrom.

[0085] In addition, the SNP mutations, the deletions, and the duplications in the genome, arising typically from conditioning with 100% CO (i.e. the third growth stage) may include, specifically with reference to the NCBI genome with accession number NZ_CP009170.1, one or both of – hypF, carbamoyltransferase, at position 136,300; and acsV, corrinoid activation / regeneration protein, at position 1,903,679.

[0086] THE INVENTION EXTENDS, AS A SECOND ASPECT THEREOF, TO an isolated, conditioned acetogen, such as T. kivui, produced according to the method of the first aspect of the invention.

[0087] The isolated, conditioned acetogen may be a selected or a mutated strain of acetogen produced according to the method of the first aspect of the invention. The isolated, conditioned acetogen may be as hereinbefore described with reference to the first aspect of the invention.

[0088] ACCORDING TO A THIRD ASPECT OF THE INVENTION, BROADLY, THERE IS PROVIDED an isolated, conditioned acetogen, such as T. kivui, comprising, relative to an unconditioned or wildtype acetogen, such as T. kivui (DSM 2030), one or more insertions in the genome, including one or more duplications such as a transposable element-induced duplication. The isolated, conditioned acetogen may comprise at least one transposon in its genome. Optionally, the isolated, conditioned acetogen such as T. kivui, including one or more insertions may further comprise at least one SNP mutation, and / or least one deletion in the genome.

[0089] The at least one insertion, including at least one duplication, and where present, at least one SNP mutation, and / or at least one deletion may arise from conditioning an unconditioned or wildtype of the acetogen in accordance with the conditioning method of the first aspect of the invention.

[0090] Duplications that may be included, specifically with reference to the NCBI genome with accession number NZ_CP009170.1, may be one or both of – at least one, optionally two, duplications of at least one of regions between 1,841,579 to 1,901,680 and 1,910,027 to 1,935,735; and the region from 1,917,220 to 1,932,727.

[0091] The duplication / s in the regions between 1,841,579 to 1,901,680 and 1,910,027 to 1,935,735 may exist to the exclusion of the duplication of the region from 1,917,220 to 1,932,727.

[0092] Duplication / s in the region from 1,917,220 to 1,932,727 may have a size of 15,507 bp. Duplication / s in the region from 1,841,579 to 1,901,680 and 1,910,027 to 1,935,735 may have a size / s of 60,101 bp and 25,708 bp respectively, or a single size of 85,809 bp.

[0093] The duplication in the region from 1,917,220 to 1,932,727 may be hydrogen- dependent CO2 reductase (HDCR). Such duplication may be in the region 1,921,445 to 1,922,281, specifically at position 1,921,445.

[0094] The duplication / s in the region of 1,841,579 to 1,901,680 may be one, more preferably both, of electron-bifurcating hydrogenase (EBH) and energy-conserving hydrogenase 2 complex (Ech hydrogenase). Such duplications may be respectively at positions 1,883,375 to 1,887,553 and 1,893,535 to 1,900,304.

[0095] The duplication / s in the region of 1,910,027 to 1,935,735 may be at least one, more preferably all, of acetyl-CoA decarbonylase / synthase complex subunit alpha (ACDS), lpdA, methylene-THF reductase, methylene-THF dehydrogenase, formate tetrahydrofolate ligase, formate / nitrite family transporter protein, hydrogen-dependent CO2 reductase (HDCR), and carbon monoxide dehydrogenase accessory protein CooC. Such duplications may respectively be at positions 1,910,148 to 1,911,086, 1,911,897 to 1,913,282, 1,913,298 to 1,914,839, 1,914,852 to 1,916,379, 1,917,220 to 1,918,899, 1,919,741 to 1,920,616, 1,921,445 to 1,927,301, and 1,934,883 to 1,935,659.

[0096] In particular, the conditioned T. kivui strain having duplication / s may be a clonal strain of T. kivui designated CO-1 having a nucleotide sequence of SEQ ID NO: 8. The nucleotide sequence may have at least 80%, 85%, 90%, 95% or above identity to the nucleotide sequence as set out in SEQ ID NO: 8, or may be a sequence which hybridises under stringent conditions to the reverse complement of the nucleotide sequence as set out in SEQ ID NO: 8.

[0097] The conditioned T. kivui strain having duplication / s may be a clonal strain of T. kivui designated CO-1 having further, or alternative, duplication / s and having a nucleotide sequence of SEQ ID NO: 9. The nucleotide sequence may have at least 80%, 85%, 90%, 95% or above identity to the nucleotide sequence as set out in SEQ ID NO: 9, or may be a sequence which hybridises under stringent conditions to the reverse complement of the nucleotide sequence as set out in SEQ ID NO: 9.

[0098] Hybridisation may occur under stringent conditions that include hybridisation in 6x sodium chloride / sodium citrate (SSC) at 40 to 45°C, followed by a wash in 0.1 to 0.2x SSC at about 60°C to about 65 °C.

[0099] SNP mutations that may be included may be one or more, typically all, of – cbiQ; rpoC; dapA; PhoU; hypF; and acsV.

[0100] More specifically, SNP mutations that may be included may be one or more, typically all, of – cbiQ, cobalt ECF transporter T component; rpoC, DNA-directed RNA polymerase subunit beta’; dapA, 4-hydroxy-tetrahydrodipicolinate synthase; phoU, phosphate signalling complex protein; hypF, carbamoyltransferase; and acsV, corrinoid activation / regeneration protein.

[0101] Even more specifically, the SNP mutations that may be included, specifically with reference to the NCBI genome with accession number NZ_CP009170.1 (SEQ ID NO: 10), may be one or more, typically all, of – cbiQ, cobalt ECF transporter T component at position 341,995; rpoC, DNA-directed RNA polymerase subunit beta’ at positions 1,969,972 and 1,970,146; and dapA, 4-hydroxy-tetrahydrodipicolinate synthase at position 818,980.

[0102] In addition, the SNP mutations that may be included, specifically with reference to the NCBI genome with accession number NZ_CP009170.1, may be one or more, typically all, of – phoU, phosphate signalling complex protein at position 1,459,688; hypF, carbamoyltransferase, at position 136,300; and acsV, corrinoid activation / regeneration protein, at position 1,903,679.

[0103] In particular, the conditioned T. kivui strain may be a clonal strain of T. kivui designated CO-1 comprising a nucleotide sequence of any of, typically all of -cbiQ, cobalt ECF transporter T component as set out in SEQ ID NO: 1; rpoC, DNA-directed RNA polymerase subunit beta’ as set out in SEQ ID NO: 2; and dapA, 4-hydroxy-tetrahydrodipicolinate synthase as set out in SEQ ID NO: 3.

[0104] In addition, the conditioned T. kivui strain may be a clonal strain of T. kivui designated CO-1 comprising a further nucleotide sequence of any of, typically all of – phoU, phosphate signalling complex protein as set out in SEQ ID NO: 4; hypF, carbamoyltransferase, as set out in SEQ ID NO: 5; and acsV, corrinoid activation / regeneration protein, as set out in SEQ ID NO: 6.

[0105] The nucleotide sequence may have at least 80%, 85%, 90%, 95% or above identity to the nucleotide sequences as set out in SEQ ID NOs: 1 to 6, or may be a sequence which hybridises under stringent conditions to the reverse complement of the nucleotide sequences as set out in SEQ ID NOs: 1 to 6.

[0106] Deletions that may be included may be full or partial deletions of one or more of – GNAT family N-acetyltransferase; DUF881 domain-containing protein; and hypothetical protein.

[0107] More specifically, deletions that may be included, specifically with reference to the NCBI genome with accession number NZ_CP009170.1, may be full or partial deletions of one or more of – GNAT family N-acetyltransferase (partial deletion from position 233,431 to 234,484); DUF881 domain-containing protein (full deletion from position 234,523 to 235,260); andhypothetical protein (partial deletion from position 235,425 to 235,869).

[0108] In particular, the conditioned T. kivui strain may be a clonal strain of T. kivui designated CO-1 comprising a nucleotide sequence of SEQ ID NO: 7. The nucleotide sequence may have at least 80%, 85%, 90%, 95% or above identity to the nucleotide sequence as set out in SEQ ID NO: 7, or may be a sequence which hybridises under stringent conditions to the reverse complement of the nucleotide sequence as set out in SEQ ID NO: 7.

[0109] MORE SPECIFICALLY, ACCORDING TO THE THIRD ASPECT OF THE INVENTION, THERE IS PROVIDED a conditioned strain of an acetogen, such as T. kivui, comprising, relative to an unconditioned or wildtype of the acetogen, such as T. kivui (DSM 2030), specifically with reference to the NCBI genome with accession number NZ_CP009170.1, having one or both duplications of – at least one, optionally two, duplications of at least one of regions between 1,841,579 to 1,901,680 and 1,910,027 to 1,935,735; and the region from 1,917,220 to 1,932,727.

[0110] The duplication / s in the regions between 1,841,579 to 1,901,680 and 1,910,027 to 1,935,735 may exist to the exclusion of the duplication of the region from 1,917,220 to 1,932,727.

[0111] Duplication / s in the region from 1,917,220 to 1,932,727 may have a size of 15,507 bp. Duplication / s in the region from 1,841,579 to 1,901,680 and 1,910,027 to 1,935,735 may have a size / s of 60,101 bp and 25,708 bp respectively, or a single size of 85,809 bp.

[0112] The duplication in the region from 1,917,220 to 1,932,727 may be hydrogen- dependent CO2reductase (HDCR). Such duplication may be in the region 1,921,445 to 1,922,281, specifically at position 1,921,445.

[0113] The duplication / s in the region of 1,841,579 to 1,901,680 may be one, more preferably both, of electron-bifurcating hydrogenase (EBH) and energy-conserving hydrogenase 2 complex (Ech hydrogenase). Such duplications may be respectively at positions 1,883,375 to 1,887,553 and 1,893,535 to 1,900,304.

[0114] The duplication / s in the region of 1,910,027 to 1,935,735 may be at least one, more preferably all, of acetyl-CoA decarbonylase / synthase complex subunit alpha (ACDS), lpdA, methylene-THF reductase, methylene-THF dehydrogenase, formate tetrahydrofolate ligase, formate / nitrite family transporter protein, hydrogen-dependent CO2 reductase (HDCR), and carbon monoxide dehydrogenase accessory protein CooC. Such duplications may respectively be at positions 1,910,148 to 1,911,086, 1,911,897 to 1,913,282, 1,913,298 to 1,914,839, 1,914,852 to 1,916,379, 1,917,220 to 1,918,899, 1,919,741 to 1,920,616, 1,921,445 to 1,927,301, and 1,934,883 to 1,935,659.

[0115] In particular, the conditioned T. kivui strain having duplication / s may be a clonal strain of T. kivui designated CO-1 having a nucleotide sequence of SEQ ID NO: 8. The nucleotide sequence may have at least 80%, 85%, 90%, 95% or above identity to the nucleotide sequence as set out in SEQ ID NO: 8, or may be a sequence which hybridises under stringent conditions to the reverse complement of the nucleotide sequence as set out in SEQ ID NO: 8.

[0116] The conditioned T. kivui strain having duplication / s may be a clonal strain of T. kivui designated CO-1 having further, or alternative, duplication / s and having a nucleotide sequence of SEQ ID NO: 9. The nucleotide sequence may have at least 80%, 85%, 90%, 95% or above identity to the nucleotide sequence as set out in SEQ ID NO: 9, or may be a sequence which hybridises under stringent conditions to the reverse complement of the nucleotide sequence as set out in SEQ ID NO: 9.

[0117] Hybridisation may occur under stringent conditions that include hybridisation in 6x sodium chloride / sodium citrate (SSC) at 40 to 45°C, followed by a wash in 0.1 to 0.2x SSC at about 60°C to about 65 °C.

[0118] The conditioned strain of acetogen, such as T. kivui, may further comprise, relative to an unconditioned or wildtype of the acetogen, such as T. kivui (DSM 2030), specifically with reference to the NCBI genome with accession number NZ_CP009170.1, one or more of – partial deletion of GNAT family N-acetyltransferase; SNP mutation of cbiQ, cobalt ECF transporter T component; full deletion of DUF881 domain-containing protein; partial deletion of hypothetical protein; SNP mutation of dapA, 4-hydroxy-tetrahydrodipicolinate synthase at position 818,980; SNP mutation of phoU, phosphate signalling complex protein at position 1,459,688; SNP mutation of rpoC, DNA-directed RNA polymerase subunit beta’ at positions 1969972 and 1970146; SNP mutation of hypF, carbamoyltransferase, at position 136,300; andSNP mutation of acsV, corrinoid activation / regeneration protein, at position 1,903,679.

[0119] More specifically, the conditioned strain may further comprise one or more of – GNAT family N-acetyltransferase (partial deletion from position 233,431 to 234,484); cbiQ, cobalt ECF transporter T component at position 341,995 (SNP mutation); DUF881 domain-containing protein (full deletion from position 234,523 to 235,260); hypothetical protein (partial deletion from position 235,425 to 235,869) (SNP mutation); dapA, 4-hydroxy-tetrahydrodipicolinate synthase at position 818,980 (SNP mutation); phoU, phosphate signalling complex protein at position 1,459,688 (SNP mutation); rpoC, DNA-directed RNA polymerase subunit beta’ at positions 1969972 and 1970146 (SNP mutation); hypF, carbamoyltransferase, at position 136,300 (SNP mutation); and acsV, corrinoid activation / regeneration protein, at position 1,903,679 (SNP mutation).

[0120] The conditioned strain may further comprise at least – cbiQ, cobalt ECF transporter T component, at position 341,995 (SNP mutation); DUF881 domain-containing protein (full deletion from position 234,523 to 235,260); hypothetical protein (partial deletion from position 235,425 to 235,869) (SNP mutation);dapA, 4-hydroxy-tetrahydrodipicolinate synthase at position 818,980 (SNP mutation); and phoU, phosphate signalling complex protein at position 1,459,688 (SNP mutation).

[0121] In one possible embodiment, the conditioned strain also comprises – hypF, carbamoyltransferase, at position 136,300 (SNP mutation); and acsV, corrinoid activation / regeneration protein, at position 1,903,679 (SNP mutation)

[0122] In a further possible embodiment, the conditioned strain further comprises – GNAT family N-acetyltransferase (partial deletion from position 233,431 to 234,484); DUF881 domain-containing protein (full deletion from position 234,523 to 235,260); and hypothetical protein (partial deletion from position 235,425 to 235,869) (SNP mutation).

[0123] In yet a further possible embodiment, the conditioned strain further comprises all of – GNAT family N-acetyltransferase (partial deletion from position 233,431 to 234,484); cbiQ, cobalt ECF transporter T component at position 341,995 (SNP mutation); DUF881 domain-containing protein (full deletion from position 234,523 to 235,260); hypothetical protein (partial deletion from position 235,425 to 235,869) (SNP mutation);dapA, 4-hydroxy-tetrahydrodipicolinate synthase at position 818,980 (SNP mutation); phoU, phosphate signalling complex protein at position 1,459,688 (SNP mutation); rpoC, DNA-directed RNA polymerase subunit beta’ at positions 1969972 and 1970146 (SNP mutation); hypF, carbamoyltransferase, at position 136,300 (SNP mutation); and acsV, corrinoid activation / regeneration protein, at position 1,903,679 (SNP mutation).

[0124] The acetogen may, in particular, be T. kivui and, therefore, the conditioned strain may be a conditioned strain of T. kivui, relative to unconditioned wildtype T. kivui (DSM 2030).

[0125] The conditioned strain may have been conditioned by performing the method of the first aspect of the invention on unconditioned or wildtype T. kivui.

[0126] The conditioned strain may be for use in performing acetogenic fermentation of CO feed gas.

[0127] ACCORDING TO A FOURTH ASPECT OF THE INVENTION, THERE IS PROVIDED a method of acetogenic fermentation of CO gas to be fermented (i.e. CO feed gas), the method including growing a conditioned strain of an acetogen, such as T. kivui, according to the second or third aspects of the invention on CO gas to be fermented (i.e. CO feed gas) as main or sole carbon source, thus producing a fermentation product.

[0128] Growing the conditioned strain may comprise culturing the acetogen in liquid growing medium (i.e. fermentation medium). For example, the liquid growing medium may be a synthetic serum medium, more specifically a chemically defined minimal medium, i.e. a growth medium that excludes growth stimulants, and in particular excludes vitamins, nutrients, and yeast extract.

[0129] The substrate of CO feed gas may comprise 100% v / v CO. Alternatively, the substrate of CO feed gas may comprise less than 100% v / v CO, for example in a range of 50% v / v CO up to 100% v / v CO.

[0130] The method of the fourth aspect of the invention is further characterised by the features of the gas fermentation process characterised with reference to the first broad aspect of the invention.

[0131] ACCORDING TO A FIFTH ASPECT OF THE INVENTION, THERE IS PROVIDED use of a conditioned acetogen, such as T. kivui, or a conditioned strain of an acetogen, such as T. kivui, according to the second or third aspects of the invention in acetogenic fermentation of CO gas to be fermented.

[0132] The use may be in accordance with the method of the fourth aspect of the invention. The CO gas may also be as described with reference to the fourth aspect of the invention.

[0133] ACCORDING TO A SIXTH ASPECT OF THE INVENTION, THERE IS PROVIDED a method of rendering a thermophilic acetogen capable of metabolizing 100%CO gas, the method including introducing one or more genetic modifications in accordance with the second or third aspects of the invention into the thermophilic acetogen.

[0134] In particular, the one or more genetic modifications may be introduction of one or more insertions including one or more duplications in accordance with the second or third aspects of the invention into the thermophilic acetogen.

[0135] BRIEF DESCRIPTION OF THE DRAWINGS

[0136] Embodiments of the invention are described below, by way of non-limiting examples, and with reference to the accompanying drawings which:

[0137] Figure 1 graphically illustrates a flow diagram of the adaptation (conditioning) steps of the invention;

[0138] Figure 2 shows the optical densities of high and low CO syngas acetogen lineages, respectively, as well as the pure CO acetogen lineage from Figure 1;

[0139] Figure 3 shows the final optical densities and acetate titers of the adapted populations, grown in triplicates in serum bottles;

[0140] Figure 4 shows the acquired acetate titers and optical densities acquired throughout the batch process on 100% CO;

[0141] Figure 5 shows growth and acetate production on high CO syngas;

[0142] Figure 6 shows a schematic representation of CO-1 duplication locus (a) and of TnCO-1 (b). Primer binding sites are indicated (P1, P2, P3, P4);

[0143] Figure 7 shows CO-1 transformation procedure with SPF-B017. CO-1 strain was cultivated in the presence of the plasmid, and further diluted with fresh mediumcontaining a final concentration of 200 mg / L of neomycin. After growth, colonies were isolated on plates containing neomycin and cultivated in liquid medium before characterization / validation; and

[0144] Figure 8 shows a serum bottle fermentation experiment where CO-1 and CO-1 SPF-B017 were cultivated for 72 hours in duplicates on various gas mixtures, OD at 660 nm is shown.

[0145] DESCRIPTION OF EMBODIMENTS OF THE INVENTION

[0146] THE INVENTION WILL NOW BE DESCRIBED in more detail with reference to experimental data collected in performing comparative conditioning of T. kivui and comparative acetogenic gas fermentation using T. kivui so conditioned. The invention is applicable to other acetogens, too, particularly thermophilic ones and the experimental data presented in relation to T. kivui is therefore presented by way of non-limiting examples only.

[0147] EXAMPLE 1

[0148] More specifically, T. kivui (DSM 2030) was conditioned in serum bottles with a 20 mL culture volume according to the method of the first aspect of the invention and alternative methods. Subsequently, conditioned strains thereof were assessed for acetogenic gas fermentation ability in various substrates by cultivation in a DasGip ® DASbox ® Mini Bioreactor System (supplied by Eppendorf AG, Hamburg, Germany). Genome characteristics and performance were analysed, under the conditions and following the procedures described below.

[0149] Growth media and organism cultivation

[0150] Two different variants of a synthetic growth medium (i.e. fermentation medium) were used, for serum bottles and bioreactors respectively.

[0151] More specifically, the media for serum bottles and bioreactors respectively were modified from Moon et al. (Moon, J., Jain, S., Müller, V., Basen, M., 2020. Homoacetogenic Conversion of Mannitol by the Thermophilic Acetogenic Bacterium Thermoanaerobacter kivui Requires External CO2. Front. Microbiol.11, 571736).

[0152] The specific compositions of the respective growth media are set out in Table 1. Table 1: Growth media compositions Serum Reactor Moon Medium bottle medium medium Species [g / L] [g / L] Na2HPO4*2H2O 7.8 7.8 NaH2PO4*H2O 6.9 6.9 K2HPO4 0.21 0.21 KH2PO4 0.16 0.16 NH4Cl 0.25 1.00 (NH4)2SO4 0.225 0.225 NaCl 0.438 0.438 MgSO4*7H2O 0.091 0.091CaCl2*2H2O 0.0060 0.0060 FeSO4*7H2O 0.0020 0.0020 KHCO3 5.41 0 Cysteine- 0.527 0.527 HCl*H2O Resazurin 0.5 mL 0.5 mL (0.2%) Traces 10 mL 10 mL DSM141* *Modified Wolin's mineral solution (https: / / www.dsmz.de / microorganisms / medium / pdf / DSMZ_Medium141.pdf)

[0153] Agar medium was made following the recipe for the serum bottle medium, with an additional 2 g / L yeast extract and 10 g / L noble agar (supplied by Carl-Roth, Schoemperlenstraße 3-5, D-76185 Karlsruhe).

[0154] Cultivation of T. kivui (DSM 2030) for adaptation (conditioning) was performed at 66°C in 125 mL serum bottles with 20 mL culture volume.

[0155] Serum bottles were incubated in a water bath shaker at medium shaking speed while the bioreactors were put in a static water bath at 66 °C.

[0156] Gases for the serum bottles were mixed with Brooks 4800 series mass flow controllers, except for CO which was added separately, and the concentration set by fraction of pressure.

[0157] For the bioreactors, premixed gases supplied by Messer Austria GmbH, Gumpoldskirchen, Austria, were used.

[0158] For serum bottles, 1 mL of cell culture was routinely transferred upon every adaptation (conditioning) step described below.

[0159] The bioreactors were inoculated to an OD600of 0.1 from 500 mL serum bottles with 100 mL culture volume.

[0160] Bioreactor cultivations

[0161] The bioreactor cultivations hereinafter described were, as mentioned above, performed in a DASbox ® Mini Bioreactor System.

[0162] Bioreactors with a 250 mL maximum volume and a working volume of 200 ml at a temperature of 66 °C were employed.

[0163] The pH was initially set to 6.4, monitored by an EasyFerm Plus K8120 pH electrode (Hamilton, Reno, NV, USA) and controlled by the addition of 5 M KOH with a MP8 multi pump module (Eppendorf AG, Hamburg, Germany).

[0164] The bioreactor was sparged with 0.05 vvm (0.6 sLh-1) of gas bought premixed from Messer Austria GmbH, Gumpoldskirchen, Austria. Microspargers made of sintered metal with a pore size of 10 μm (Sartorius Stedim Biotech GmbH, Göttingen, Germany) were used to improve gas transfer into the liquid phase.

[0165] Prior to inoculation, the reactor medium was flushed with the appropriate gas for at least 3h.

[0166] In continuous cultivation, as opposed to batch cultivation, anaerobic feed medium was continuously added to growth medium inside the bioreactor at the specified dilution rate with the MP8 pump module. To keep the reaction volume constant, culture broth was continuously removed by peristaltic pumps (Ismatec SA, Glattburg, Germany) and a dip tube, maintaining culture volume around 200 mL.

[0167] Feed bottles were kept anaerobic by applying an overpressure of 0.1 bar to the headspace with N2 and a pressure reducer.

[0168] Steady state conditions were examined after at least 4 volume changes and OD600 was measured on a regular basis.

[0169] For dry biomass, culture broth was centrifuged at 10,000 g for 5 minutes and washed two times with 0.9% NaCl before being transferred into a glass tube with RO (reverse osmosis) water.

[0170] The supernatant of the culture broth was used for HPLC analysis.

[0171] HPLC analysis

[0172] Substrates and products in liquid medium were analysed with an Aminex HPX-87H column (300 × 7.8 mm) supplied by Bio-Rad, Hercules, CA, USA, using an Ultimate 3000 system supplied by Thermo Scientific, Waltham, MA, USA).4 mM H2SO4was used as a mobile phase and the column was operated at 60°C at a flow rate of 0.6 ml min-1for 20 min.

[0173] A 10 μl sample was injected onto the column. Detection was performed using a refractive index (Refractomax 520, Thermo Fisher Scientific, Waltham, MA, USA) and a diode array detector (Ultimate 3000, Thermo Fisher Scientific, Waltham, MA, USA). Chromeleon 7.2.6 Chromatography Data System (Thermo Fisher Scientific, Waltham, MA, USA) was used for control, monitoring and evaluation of the analysis.

[0174] 540 μl of culture supernatant was mixed with 60 μL of 40 mM H2SO4and centrifuged for 5 min at 14,000 rpm (21,913 g) at 4°C. The remaining supernatant was used for further analysis. Standards at defined concentrations of acetate and glucose were treated the same way. A five-point calibration was used for quantification.

[0175] Genome sequencing

[0176] Cells were grown to late log phase (OD600~ 1), harvested by centrifugation and frozen at -80°C.

[0177] CO adaptation (conditioning)

[0178] Wildtype T. kivui (DSM2030) was adapted (conditioned) for CO metabolization in accordance with the method of the first aspect of the invention, by growing T. kivui for three growth cycles in the first growing stage, two growth cycles in the second growing stage, and five growth cycles in the third growing stage in 30% v / v CO, 40% v / v CO, 50% v / v CO, 60% v / v CO, and 100% v / v CO respectively.

[0179] Conditioning was done without addition of any growth stimulants, i.e. free, of vitamins or yeast extract.

[0180] For comparative purposes, after three passages (growth cycles) on H2 / CO2, the strain was grown twice on two different mixes of H2 / CO2 / CO called “low CO syngas” (30 % CO, 9 % CO2, 58 % H2, 3 % N2), as comparison, and “high CO syngas” (52 % CO, 21 % CO2, 24 % H2, 3 % N2), in accordance with the invention, and then transferred to respective serum bottles containing 30% CO in the headspace.

[0181] More specifically, as shown in Figure 1, starting from a mixotrophic culture, wildtype T. kivui was grown three times on H2 / CO2gas phase only, for subsequent clone isolation and gene sequencing. The strain from the same vessel was transferred to two different synthetic syngas mixtures, namely low CO syngas and high CO syngas respectively, as described above.

[0182] It was surprisingly found that, after the second transfer on the high CO syngas mix, growth on 30% CO was already facilitated, whereas transfer from low CO syngas did not yield any growth on 30% CO (data not provided). CO concentration could be increased in 10% increments from 30 to 60% with every transfer of T. kivui grown on the high CO syngas, however, with continuing growth being observed.

[0183] Using a strain from the 60% culture, transfer and growth on 100% CO gas phase was possible in a single step. Therefore, the adaptation was conducted in a total of ten transfers, namely three on H2 / CO2and seven on CO-containing gas, five of which were on CO alone.

[0184] Surprisingly, a strong disposition of the strain to grow on pure CO in the wildtype was observed by this step-wise conditioning method. This was not expected prior to the experiments.

[0185] The H2 / CO2, low and high CO syngas strains, as well as the 100% CO grown strain were plated and single colonies isolated for further characterization and gene sequencing.

[0186] It was therefore found that only the culture grown on high CO syngas was able to grow on 30% CO and could be subsequently brought to grow on 100% CO in four more transfers. Reference in this regard is made also to Figure 1, which shows, diagrammatically, a flow diagram of the adaptation (conditioning) steps applied.

[0187] As the analysis that follows shows (see Table 4 in particular), the T. kivui strain identified as CO-1, a clonal strain obtained from T. kivui adapted by performing the method of the first aspect of the invention, was surprisingly found to be capable of co- utilization of H2 and CO at growth rates which are, surprisingly, higher than any other acetogen reported in literature known to the applicant, while growing on a minimal medium (again, see Table 4 in this regard). This is remarkable, because both aspects for themselves are of commercial interest, and even more their combination.

[0188] The adaptation produced four different populations adapted to H2 / CO2, low and high CO syngas, as well as 100% CO. The adaptation was noted by an increase in OD600as compared to control cultures with the same H2 / CO2content in the headspace but using N2 instead of CO. Reference is in this regard made to Figure 2, which shows opticaldensities of high and low CO syngas lineages, respectively, as well as the pure CO lineage from Figure 1.

[0189] As can be seen from Figure 2, increasing CO concentration in the headspace of serum bottles allowed for dense growth of T. kivui on 100% CO in seven passages in total (H2 / CO2 → high CO syngas → incremental 10% increases from 30% to 60% and then a jump up to 100% CO in the headspace).

[0190] From H2 / CO2 and CO adapted cultures, the populations were plated, and single colonies harvested to attain genetically uniform strains.

[0191] The colony from the H2 / CO2grown population is labelled G1, and three clonal strains from the CO grown population are labelled CO-1, CO-2 and CO-3. Each underwent genome analysis.

[0192] Genome analysis

[0193] Adapted (conditioned) populations (low CO syngas, high CO syngas, 100% CO) were directly submitted to genome mutation analysis.

[0194] From the pure CO population, colonies were also isolated on medium containing Noble agar (10 g / L) and screened for their ability to grow on 100% CO. Three different clonal strains were obtained and submitted for genome sequencing, identified as CO-1, CO-2, and CO-3 respectively.

[0195] Sequencing data was used to perform SNP analysis. Table 2 shows a summary of the different mutations identified in the strains obtained from the low CO syngas, high CO syngas and 100% CO populations. Table 3 shows a summary of the different mutations identified in clonal strains CO-1, CO-2 and CO-3, wherein only mutations with frequency >90% are reported and silent mutations were filtered out. Table 2: Mutations in low CO syngas, high CO syngas, and 100% CO conditioned strains. Low CO Syngas Population Mutation Locus Tag Product Position Ref. Alt. Freq. FCWTType Missense TKV_RS00550 membrane protein 110469 C G 24% 3.3 (P75A) Intergenic - 136048 CT C - 11% 1.5 cobalt ECF Insertion TKV_RS01675 transporter T 341995 T C 69% 1.0 (X207fs) component cbiQ ATP-binding Missense TKV_RS01680 cassette domain- 342421 C T 60% 3.0 (P92S) containing protein IS200 / IS605 family Missense 13** TKV_RS13215 accessory protein 432209 G C - (G434A) % TnpB-related protein amino acid Missense TKV_RS03470 704424 T A 20% 3.3 permease (T57S) Intergenic - 704604 A AT - 18% 5.6 Intergenic - 759157 CA C - 12% 1.24-hydroxy- Missense TKV_RS04105 tetrahydrodipicolinat 818980 C G 27% 13.8 (A93P) e synthase sensor histidine Missense TKV_RS04285 851211 C T 17% 3.7 kinase (D329N) penicillin-binding Insertion TKV_RS04390 873559 T TA 46% 3.1 protein 2 (M576fs) Missense TKV_RS06290 aspartate kinase 1240652 C G 37% 10.4 (G342A) 1-deoxy-D-xylulose- Missense TKV_RS06405 5-phosphate 1264984 G C 14% - (Q358E) reductoisomerase type I glyceraldehyde-3- Missense TKV_RS07960 1559965 T C 100% 1.0 phosphate (N35D) dehydrogenase CRISPR-associated Missense TKV_RS08460 1670432 G C 50% 18.5 CARF protein Csx1 (H215D) [FeFe] hydrogenase, Missense TKV_RS09720 1922486 C A 17% 5.8 group A (G440V) DNA-directed RNA Missense TKV_RS09895 polymerase subunit 1950405 G A 50% 32.3 (S168F) alpha DNA-directed RNA Missense TKV_RS10075 polymerase subunit 1976392 C G 23% 3.0 (G113R) betaDNA repair protein Missense TKV_RS10195 1995865 C A 52% 7.8 RadA (R238I) carbamoyl- phosphate synthase Missense TKV_RS10830 (glutamine- 2122220 C G 54% 15.9 (R582T) hydrolyzing) large subunit DHH family Missense TKV_RS11995 2376288 A T 59% 2.0 phosphoesterase (M82K) High CO Syngas Population Mutation Locus Tag Product Position Ref. Alt. Freq. FCWTType stage 0 sporulation Nonsense TKV_RS00500 100921 C T 78% - family protein (Q84X) Missense TKV_RS00610 AAA family ATPase 124880 A G 12% - (T350A) DUF881 domain- Deletion TKV_RS01125 234579 CT C 80% 6.0 containing protein (V228fs) cobalt ECF Insertion TKV_RS01675 transporter T 341995 T C 92% 1.3 (X207fs) component cbiQ ATP-binding Missense TKV_RS01680 cassette domain- 342421 C T 73% 3.6 (P92S) containing protein ATP-binding Missense TKV_RS01680 cassette domain- 342746 A C 12% - (H200P) containing proteinflagellar motor Missense TKV_RS02635 535038 G A 11% - protein (E269K) flagellar motor Missense TKV_RS02640 535038 G A 11% - protein MotB (M1I) TATAGCTT Deletion TKV_RS03600 hypothetical protein 729103 TAGA (SEQ T 31% - (I150fs) ID NO: 11) Intergenic - 759157 CA C NA 12% 1.2 penicillin-binding Insertion TKV_RS04390 873559 T TA 10% 0.7 protein 2 (M576fs) Intergenic - 1134756 G T - 30% 1.6 type II secretion Missense TKV_RS05675 system ATPase 1136321 C T 12% - (S518L) GspE polyamine Missense TKV_RS06070 aminopropyltransfera 1197002 A G 13% - (T54A) se YlzJ-like family Missense TKV_RS06280 1239704 C A 14% - protein (M1I) prolipoprotein Missense TKV_RS07855 diacylglyceryl 1539981 C T 61% 4.8 (G200R) transferase type I glyceraldehyde-3- Missense TKV_RS07960 1559965 T C 100% 1.0 phosphate (N35D) dehydrogenaseMissense TKV_RS07975 acylphosphatase 1562892 T A 14% - (N53Y) metalloregulator Missense TKV_RS09310 ArsR / SmtB family 1847332 C G 41% - (W65C) transcription factor Intergenic - 1869603 C T - 67% - DNA-directed RNA Missense TKV_RS10070 polymerase subunit 1969972 C T 52% - (G1002E) beta DNA-directed RNA Missense TKV_RS10070 polymerase subunit 1970146 G T 12% - (A944D) beta transcription Missense TKV_RS10100 termination / antitermi 1979737 T A 13% - (K28I) nation protein NusG Intergenic - 2268120 G C - 52% 5.7 DHH family Missense TKV_RS11995 2376288 A T 77% 2.5 phosphoesterase (M82K) 100% CO population Mutation Locus Tag Product Position Ref. Alt. Freq. FCWTType chromosomal Missense TKV_RS00005 replication initiator 107 G A 63% - (G3R) protein DnaA stage 0 sporulation Nonsense TKV_RS00500 100921 C T 82% - family protein (Q84X)carbamoyltransferas Missense TKV_RS00680 136300 G C 23% - e hypF (G22A) DUF881 domain- Deletion TKV_RS01125 234579 CT C 99% containing protein (V228fs) cobalt ECF Insertion TKV_RS01675 transporter T 341995 T C 99% 1.4 (X207fs) component cbiQ ATP-binding Missense TKV_RS01680 cassette domain- 342421 C T 17% 0.8 (P92S) containing protein ATP-binding CT Insertion TKV_RS01680 cassette domain- 342777 C 37% 6.3 A (K215fs) containing protein DUF1648 domain- Missense TKV_RS01745 355062 G C 24% - containing protein (V94L) TATAGCTT Deletion TKV_RS03600 hypothetical protein 729103 TAGA (SEQ T 39% - (I150fs) ID NO: 11) 4-hydroxy- Missense TKV_RS04105 tetrahydrodipicolinat 818980 C G 82% 41.7 (A93P) e synthase penicillin-binding Insertion TKV_RS04390 873559 T TA 48% 3.2 protein 2 (M576fs) Missense TKV_RS05625 ribonuclease J 1125479 G A 20% -type II secretion Missense TKV_RS05675 system ATPase 1136321 C T 17% - (S518L) GspE Missense TKV_RS05745 TIM barrel protein 1146134 G C 42% - (S269T) phosphate signaling Missense TKV_RS07415 complex protein 1459688 C T 87% - (D215N) PhoU UDP-N- acetylmuramoyl-L- Missense TKV_RS07535 alanyl-D-glutamate- 1483593 C A 17% - (G334C) 2, 6-diaminopimelate ligase type I glyceraldehyde-3- Missense TKV_RS07960 1559965 T C 100% 1.0 phosphate (N35D) dehydrogenase HPr family Missense TKV_RS08245 phosphocarrier 1625737 C T 23% - (G67R) protein Intergenic - 1676464 G A - 11% - metalloregulator Missense TKV_RS09310 ArsR / SmtB family 1847332 C G 43% - (W65C) transcription factor Intergenic - 1869603 C T - 53% - nickel-dependent Missense TKV_RS09610 hydrogenase large 1899612 G T 62% - (H109N) subunitIntergenic - 1900320 G C - 14% - DNA-directed RNA Missense TKV_RS10070 polymerase subunit 1969972 C T 74% - (G1002E) beta DNA-directed RNA Missense TKV_RS10070 polymerase subunit 1970146 G T 26% - (A944D) beta Intergenic - 2268120 G C - 31% 3.4 DHH family Missense TKV_RS11995 2376288 A T 31% 1.0 phosphoesterase (M82K) Table 3: Genetic modifications in CO-1, CO-2, and CO-3. Frequency cutoff of 10% was used and silent mutations were filtered out. CO-1 Locus Tag Product Position Ref. Alt. Modification Type Freq. FCWTcarbamoyltransferase TKV_RS00680 136300 G C Missense (G22A) 100% - hypF cobalt ECF transporter TKV_RS01675 341995 T C Insertion (X207fs) 100% 1.4 T component cbiQ 4-hydroxy- TKV_RS04105 tetrahydrodipicolinate 818980 C G Missense (A93P) 100% 50.9 synthase TKV_RS05745 TIM barrel protein 1146134 G C Missense (S269T) 100% - TKV_RS06280 YlzJ-like family protein 1239704 C A Missense (M1I) 100% - phosphate signaling TKV_RS07415 1459688 C T Missense (D215N) 100% - complex protein PhoUtype I glyceraldehyde- TKV_RS07960 3-phosphate 1559965 T C Missense (N35D) 100% 1.0 dehydrogenase stalk domain- TKV_RS08050 1576833 C G Missense (E349D) 100% - containing protein corrinoid TKV_RS09640 activation / regeneration 1903679 C G Missense (G411A) 100% - protein AcsV DNA-directed RNA TKV_RS10070 polymerase subunit 1970146 G T Missense (A944D) 100% - beta Intergenic - 2268120 G C - 100% 11.0 CO-2 Locus Tag Product Position Ref. Alt. Modification Type Freq. FCWTcobalt ECF transporter TKV_RS01675 341995 T C Insertion (X207fs) 100% 1.4 T component cbiQ 4-hydroxy- TKV_RS04105 tetrahydrodipicolinate 818980 C G Missense (A93P) 99% 50.5 synthase TKV_RS04565 acyl-CoA ligase 903470 G T Nonsense (G383X) 99% - PIG-L family TKV_RS05260 1055168 G A Missense (T193M) 100% - deacetylase TKV_RS05625 ribonuclease J 1125479 G A Missense (M51I) 100% - phosphate signaling TKV_RS07415 1459688 C T Missense (D215N) 100% - complex protein PhoU Intergenic - 1528260 G A - 100% -type I glyceraldehyde- TKV_RS07960 3-phosphate 1559965 T C Missense (N35D) 100% 1.0 dehydrogenase DNA-directed RNA TKV_RS10070 polymerase subunit 1970146 G T Missense (A944D) 100% - beta Intergenic - 2268120 G C - 100% 11.0 CO-3 Locus Tag Product Position Ref. Alt. Modification Type Freq. FCWTIntergenic - 303329 T A - 100% 8.073501 ECF transporter S TKV_RS01555 322778 TG T Deletion (G128fs) 97% - component cobalt ECF transporter TKV_RS01675 341995 T C Insertion (X207fs) 100% 1.399329 T component cbiQ flagellar export TKV_RS02415 486030 G T Missense (A116S) 100% - chaperone FliS 4-hydroxy- TKV_RS04105 tetrahydrodipicolinate 818980 C G Missense (A93P) 100% 50.9 synthase TKV_RS05625 ribonuclease J 1125479 G A Missense (M51I) 100% - TKV_RS06280 YlzJ-like family protein 1239704 C A Missense (M1I) 100% - phosphate signaling TKV_RS07415 1459688 C T Missense (D215N) 100% - complex protein PhoU type I glyceraldehyde- TKV_RS07960 3-phosphate 1559965 T C Missense (N35D) 100% 1 dehydrogenaseDNA-directed RNA TKV_RS10070 polymerase subunit 1970146 G T Missense (A944D) 100% - beta

[0196] To complement point mutation analysis, Illumina read coverage was analyzed for the different conditioned variants (low, high syngas, pure CO populations, as well as clonal CO-1, CO-2 and CO-3 strains). Comparison to wildtype read coverage shows uneven read distribution along the genome, with stark differences in two specific loci. The first locus shows a ca. 2.5 kb deletion (positions 233,431 to 235,869) in the pure CO populations, as well as in the derived clones (CO-1, CO-2, CO-3). This deletion is not present in low and high syngas populations. It inactivates / deletes two genes with unknown functions as well as a GNAT family N-acetyltransferase, which could be involved in post- translational gene regulation.

[0197] The second locus shows an increased distribution of reads across two large genome regions in close proximity (region 1: positions 1,841,579 to 1,901,680, 60,101 bp; region 2: positions 1,910,027 to 1,935,735, 25,708 bp). In those regions, read coverage is approximately twice that of the rest of the genome (mean read coverage ± SD in CO-1 NGS data: region 1: 1686.1 ± 253.4 reads; region 2: 1642.1 ± 218.9 reads; whole genome: 718.0 ± 217.6 reads). This indicates that these two regions have been duplicated in the genome. This pattern can also be seen in the pure CO population dataset, but not in the low syngas dataset. For the high syngas dataset, only a portion of the rearrangement can be observed (positions 1,917,220 to 1,932,727; 15,507 bp). This portion includes parts of the Wood-Ljungdahl pathway (WLP) responsible for autotrophy in acetogens. In particular, genes encoding the different subunits of the hydrogen-dependent CO2reductase (HDCR, TKV_RS09715 to TKV_RS09735) seem to be duplicated. In the resulting strain, the HDCRis therefore likely to be overexpressed, which probably has a beneficial impact for growth on CO as the HDCR is known to be inhibited by CO, thereby preventing / limiting autotrophy in the presence of CO. Given that the high syngas population can grow on a gas mixture comprising 52% CO and that both the low syngas and WT strain cannot, the rearrangement likely is a key factor for CO tolerance and / or CO catabolism. In the strains adapted to grow on pure CO (100% CO population, CO-1, CO-2 and CO-3 clonal strains), the putative duplication in region 2 is extended and comprises most of the genes involved in the WLP, with the exception of those encoding the CO dehydrogenase (TKV_RS09795), subunits of the acetyl-CoA synthase (TKV_RS09650-55-60) and for the phosphotransacetylase / acetate kinase (TKV_RS06770-75). Large-scale duplication of the WLP is likely to consolidate the effect of the smaller duplication observed in the high syngas population by facilitating gas uptake in the presence of CO and could therefore be the key driver conferring the ability to grow on 100% CO in the CO population and derived clones.

[0198] Figure 3 shows the final optical densities and acetate titers of the adapted populations, grown in triplicates in serum bottles. There is a notable increase in OD with higher energy availability in the gas phase (same-colored bars with asterisks represent two sample t-tests with assumed unequal variances: * represents p<=0.05 ** represents p<=1*10-2*** represents p<=1*10-3). Thereafter, there is a significant difference in optical densities between all gas compositions. This difference is not represented in the acetate titers, where the only significant difference was found between low CO syngas and H2 / CO2.

[0199] Cultures grown on CO exhibit an overall higher variability and significantly higher optical densities than on the other gas mixes. The final OD600 grown on 100% CO was determined at 1.14 ± 0.14, which is 2.43x higher than the final OD600reported inWeghoff et al. (2016) at 0.47. Similarly, acetate titer of 5.44 ± 1.10 g / L is 2.1-fold higher than the reported acetate titer of 2.65 g / L on 70% CO (100% CO is not stated).

[0200] Cell and acetate titers of the acquired strain are remarkably high, and the growth rate on carbon monoxide is also significant for acetogenic gas fermentation (Table 4). E. limosum, and C. carboxidivorans are known to be fast growing strains on CO (both of which grow on complex medium). C. autoethanogenum showing the fastest growth also in continuous cultures is used in industrial applications and has undergone numerous generations of adaptive evolution in bioreactors.

[0201] Table 4: Comparison of growth rates of different acetogens on CO or derivatives thereof (* = calculated from the data provided by the inventors) Strain Source Carbon Synthetic Culture Max. Growth source medium conditions rate [h-1] T. kivui CO1 Present 100% CO x Bioreactor, 0.25 + / - 0.03 invention batch culture T. kivui CO1 Present High CO x Bioreactor, 0.20 + / - 0.03 invention syngas batch culture T. kivui Present High CO x Bioreactor, 0.18 invention syngas continuous culture T. kivui (Weghoff 100% CO Serum bottles 0.021 and Müller, 2016)1E. limosum (Jin et al., 66% CO Serum bottles 0.11 2022)2E. limosum (Kang et 44% CO Serum bottles 0.089 al., 2020)3syngas E. limosum (Pregnon 200 mM x Serum bottles 0.076 et al., MeOH 2022)4H. pseudoflava (Grenz et 40% CO x Serum bottles 0.06 al., 2019)5syngas C. ljungdahlii (Zhu et al., 80% CO Serum bottles 0.094 + / - 0.008 2020)*6C. carboxidivorans (Lanzillo et 100% CO Serum bottles 0.100 ± 5.5 × al., 2020)710−4C. (de Lima et 60% CO x Bioreactor, 0.12 autoethanogenum al., 2022)8continuous culture

[0202] Since final titers offer only limited insight in the characterization of a new strain, bioreactor cultivations were grown. Batch cultivation offers the possibility to observe maximum growth, production and gas uptake rates, however it does not resemble an economically feasible process. Therefore, continuous cultivations were grown as well, where the cell broth containing product is continuously diluted and cells never go into senescence. Since the medium for T. kivui is relatively inexpensive, and can be recycled, continuous processing is favorable.

[0203] Batch fermentation

[0204] T. kivui was grown in two different batches in duplicate. T. kivui was grown on 100% CO as well as high CO syngas (52% CO, 21% CO2, 24% H2), to feature the high potential of the strain to grow in CO as well as the ability to co-utilize H2and CO.

[0205] Figure 4 shows the acquired acetate titers and optical densities acquired throughout the batch process on 100% CO. The culture displayed a lag phase of around 12 hours, followed by two different growth phases (Figure 3 and Table 5). The titers reached in this experiment are significantly higher compared to the syngas fermentation, and a OD600 of 4.85 (= 2.03 gCDM L-1) (CDM = cell dry mass) and an acetate titer of 32.48 g / L was observed.

[0206] Also of note is that the cells catalyzed a water-gas shift reaction after 40h, where no growth occurred (results not shown). CO uptake of the cells is roughly constant over the whole experimental period. After growth and acetate production ceased, cells catalytically converted CO into H2and CO2as outlined by negative uptake rates (i.e. production rates) for H2 and CO2 after 40 h cultivation (Figure 4).

[0207] Table 5: Parameters of growth phases in batches on high CO syngas and 100% CO compared. µ average [h-1] r Acetate average [g L-1h-1] Growth phase Period [h-h] Syngas CO Syngas CO 1 6-13 0.20 0.18 0.32 0.21 2 13-19 0.13 0.25 0.68 0.46 3 20-38 0.03 0.05 0.53 0.69

[0208] Figure 5 features growth and acetate production on high CO syngas. Peak OD600was 2.89 (= 1.28 gCDM L-1) and acetate titer was 19.9 g / L on average. These valuesrepresent 63.1 and 61.2 % respectively of the titers reached when grown on 100% CO, which could show that the titers yielded are a function of the energy content in the gas substrate, and also shows how acetate production and growth are directly coupled.

[0209] Continuous process

[0210] Because syngas is a more likely scenario for production of acetate from process fumes, a continuous process was conducted with different production parameters.

[0211] Two highly productive continuous processes were stably established with T. kivui on syngas. One was done to reach a specific growth rate (High dilution rate) and the other was done to maximize acetate titer (high titer). Both reached roughly the same productivities (Table 6).

[0212] Table 6: Continuous process key parameters with T. kivui adapted to 100% CO. High dilution rate High titer Input Dilution rate [1 / h] 0.179 0.074 Gassing rate [vvm] 0.068 0.066 Stirrer speed [rpm] 1200 900 pH 6.4 6.4 Output CDM [g / L] 0.41 0.51 OD600 1.24 1.78 cAcetate [g / L] 5.73 12.94rAcetate[g / L / h] 1.022 0.953 H2UR [mmol / L / h] 22.1101 0.9782 CO UR [mmol / L / h] 60.4105 59.4268 CO2 UR [mmol / L / h] -2.0783 -5.7367 UR = uptake rate; vvm = vessel volumes per minute. Rpm = stirrer speed, revolutions per minute.

[0213] DISCUSSION

[0214] The following statements discuss pertinent features of the invention and further characterise the invention.

[0215] Conditioning

[0216] Differentiation to Weghoff and Müller (2016):

[0217] In the present invention, the inventors did not directly subject wildtype acetogens to CO as sole gaseous carbon and energy source. Rather, the inventors used H2 / CO2cultures and transferred them to a syngas mixture using chemically defined minimal medium. This procedure was surprisingly found to allow T. kivui to adapt to the presence of CO while being able to utilize “familiar” growth substrates (H2 / CO2present in the syngas).

[0218] Only after this initial conditioning step was the strain exposed to a strong selection pressure of growing in the presence of CO as sole carbon and energy source (with no other sources provided via yeast extract). Incremental increases in CO surprisingly allowed for adaptation of cells to the use of CO as sole carbon and energy source (rather than H2 / CO2 used by the wildtype). At 60% CO in the gas phase, the inventors exposedcells again to a strong selection pressure by increasing CO concentration to 100% within one passage.

[0219] The inventors furthermore used a detour via syngas to adapt T. kivui to growth on pure CO.

[0220] In addition, the inventors surprisingly found that they used strong enough selection pressure to force adaptation. For example, the inventors found that transfer of T. kivui grown on low CO syngas to 30% pure CO was unsuccessful. The inventors were only successful with adaptation by applying a strong selection pressure of, sequentially, applying H2 / CO2 to high CO syngas, high CO syngas to 30% CO, 60% pure CO to 100% pure CO) and “recovery” phases (sub-passaging on high CO syngas before transferring to 30% pure CO, incremental increase from 30 to 60% pure CO before transferring to 100 % pure CO).

[0221] Significantly, the inventors also relied on the use of chemically defined medium without vitamins and yeast extract.

[0222] Differentiation to other studies with syngas:

[0223] In other studies of which the inventors are aware, syngas alone was used to adapt acetogens to growth on syngas (e.g. C. autoethanogenum, 142 generations, Ingelman et al., 2023), E. limosum, 400 generations, Jin et al., 2022).

[0224] The approach that the inventors follows and that surprisingly yielded the results discussed herein was to use syngas first, then CO. This not only yielded cells that can grow well in 100% CO, but also grow at higher specific growth rates on syngas.

[0225] General

[0226] Much faster adaptation of T. kivui (~31 generations) to growth on pure CO and syngas at higher growth rates (µ= 0.2-0.24 h-1) was surprisingly observed compared to C. autoethanogenum (142 generations, µ = 0.12 h-1) and E. limosum (400 generations, µ = 0.11 h-1)

[0227] The inventors believe that the method of the invention can be combined with UV or chemical mutagenesis (e.g. via EMS) to increase mutagenesis rate. EMS stands for ethyl methanesulfonate, which is a chemical mutagen commonly used in genetics research to induce mutations in DNA. EMS alkylates DNA bases, causing them to mispair during replication and leading to mutations in the resulting DNA sequences. This chemical is often used in conjunction with other mutagenic techniques, such as UV radiation, to increase the overall mutation rate in an organism's genome.

[0228] Furthermore, the method of the invention may be applied in continuous gas fermentations to obtain superior phenotypes (e.g. educt or product tolerance) when suitable selection pressure is applied.

[0229] Subculturing of the mutated T. kivui strain on glucose for 40 generations was found not to result in reversion of the phenotype.

[0230] The adapted strains were found to be robust with regard to CO growth, i.e. when they were subjected again to gasses with low CO concentration and then back tohigh CO containing gasses, they could still demonstrate high growth rates, so the adaptations were found to be long-lasting / permanent.

[0231] In further experiments, it was found that the process and strains are robust against impurities as they are present in synthesis gas from biomass and waste gasification, such as dust, tars and sulphur-containing compounds.

[0232] The process disclosed in this specification was found to work with pure and mixed cultures in a bioreactor, where all strains are anaerobic.

[0233] For downstream processing, the methods known to the state-of-the-art can be applied, such as centrifugation for winning biomass in case of intracellular products. For extracellular products, in-situ techniques are particularly advantageous. Low-boiling point compounds such as acetone can be vaporized in case of thermophilic fermentations. Membrane processes also lend themselves for product abstraction, e.g. electrodialysis or dialysis. Solvent extraction, e.g. with ionic liquids, also can be applied.

[0234] EXAMPLE 2

[0235] Long-read sequencing, de novo assembly of CO-1, identification of TnCO-1

[0236] Conditioned CO-1 produced according to the method of the invention was autotrophically grown on CO as sole carbon and energy sources in mineral medium. gDNA was extracted by treating cells with lysozyme and by using the Zymo Quick DNA miniprep kit according to the manufacturer’s specifications. Extracted gDNA was sent to PlasmidSaurus (Eugene, Oregon, USA) for Oxford Nanopore Technology (ONT) sequencing. Library was prepared with the Rapid Barcoding Kit 96 V14 (SQK-RBK114.96,ONT) according to the manufacturer’s instructions, without DNA shearing or size selection. Sequencing was performed on a PromethION with an R10.4.1 flowcell. Basecalling, barcode splitting and adapter trimming was performed with Guppy (v.6.4.6) in super-high accuracy mode, which resulted in 390,315 raw reads (N50 = 5,697). Down sampling to 100X coverage was performed with Seqkit v2.4.0, sorting for longest reads and resulting in 15,957 reads (N50 = 15,344).

[0237] Draft assembly was performed with Canu v2.2 with default parameters, yielding 5 linear contigs. Overlaps of both ends of the longest contig (2,424,656 bp) were determined by BLAST. The resulting 2,396,975 bp contig was subsequently circularized, annotations were transferred from T. kivui DSM 2030 published genome (NZ_CP009170.1) using Geneious 2023.2.1 and the resulting sequence was rotated to start at dnaA as the start gene. Based on its length and on the DSM 2030 chromosome length (2,397,824 bp), this sequence was identified as the CO-1 chromosome. For the 4 remaining contigs (36,204 bp, 35,793 bp, 55,987 bp and 60,479 bp), regions overlapping the chromosomal contig were found at the duplication sites previously determined through Illumina sequencing using BLAST. These 4 contigs significantly overlapped between each other, which allowed the draft assembly of a single, circular extrachromosomal element (85,811 bp). This element was found to encompasses a CDS coding for an IS1182-like transposase shown as SEQ ID NO: 12, and is further referred to as TnCO-1.

[0238] Validation of TnCO-1

[0239] Sequence analysis enabled the identification of novel sequence junctions specific to CO-1. In turn, this allowed the design of junction-specific primers (Figure 6a and 6b, and Table 7 primer sequences). These primers can anneal onto the chromosome, buttheir orientation prevents successful amplification via PCR. On the other hand, amplification from TnCO-1is designed to yield short PCR products (1,055 and 468 bp). Primers targeting chromosomal DNA (pyrE gene) were used as control. PCR on DNA extracted from CO-1 and from G1 (the wildtype (WT) derivative) grown with different carbon sources (glucose, H2 / CO2 and CO, when possible) was further performed using Phusion DNA polymerase (NEB), which unambiguously showed the presence of the junctions in CO-1 only (results not shown), indicating that TnCO-1indeed exists in vivo.

[0240] Table 7: Primer sequences Name Sequence Use ASI127TACCGTCGGATACGATGTCCAmplification of pyrE (SEQ ID NO: 14)(chromosome) ASI128CGTGATTGCGGGTTTGTCTGAmplification of pyrE (SEQ ID NO: 15)(chromosome) P1CTTGTGTATGGTACTGCTGGAmplification of junction (SEQ ID NO: 16)P1 / P2 (TnCO-1) P2GCTCCCCTTTTTCTATATCC (SEQAmplification of junction ID NO: 17)P1 / P2 (TnCO-1) P3CACTTCCATTCACTCATGTC (SEQAmplification of junction ID NO: 18)P3 / P4 (TnCO-1) P4AGGGGCGATATTTAAGATGGAmplification of junction (SEQ ID NO: 19)P3 / P4 (TnCO-1) pMU_seq_3GGTGGGAGAAAATGAAAACCAmplification of neoR (SEQ ID NO: 20)(SPF-B017) ASI_057GCTCTTGATCCGGCAAACAAAmplification of neoR (SEQ ID NO: 21)(SPF-B017) CCCGTATGAATTTAmplification of CO-1 RH125TACTGTG (SEQID NO: 22)deletion locus (chromosome) 26GAmplification of CO-1 RH1CCTATTACAGATATCTTGCTC(SEQ ID NO: 23)deletion locus (chromosome)

[0241] CO-1 transformation and loss of TnCO-1

[0242] CO-1 was transformed with the E. coli – Thermoanaerobacter shuttle vector SPF-B017, SEQ ID NO: 13 (a derivative of commonly used pMU131, Shaw et al.2010) using an established method based on natural competency (Basen et al. 2018). Thismethod was slightly modified, as selection was performed in liquid medium with 200 mg / L neomycin (Figure 7). After isolation of a single clone (referred to as CO-1 SPF-B017), a serum bottle gas fermentation experiment was performed (Figure 8). 72h fermentation surprisingly showed a much lower capacity to grow on high syngas mix for CO-1 SPF- B017 as compared to CO-1, as well as an inability to grow on CO as sole carbon and energy source.

[0243] To further characterize this loss of function, CO-1 SPF-B017 gDNA was extracted, and genotyped using PCR. The junction-specific primers described previously were used, and two additional pairs were also included. One primer pair was used to discriminate for CO-1 chromosome. As shown previously, CO-1 chromosome indeed displays a deletion at a specific locus, which can be used to assess whether the strain used indeed stemmed from CO-1. Another primer pair was used to amplify the neomycin resistance gene bore by SPF-B017 plasmid. PCR showed unambiguously that TnCO-1 was lost in CO-1 SPF-B017 (results not shown).

[0244] Finally, CO-1 SPF-B017 was grown on gas (H2:CO2:CO: 60:15:25) and gDNA was extracted and submitted to ONT sequencing, similarly as for CO-1. Raw reads (575,125 reads, N50 = 3,737) were parsed using Seqkit v2.4.0 for junction-specific sequences (given thereafter), which could not be found in any of the reads. Finally, raw reads were aligned to the DSM 2030 WT genome (using Geneious 2023.2.1, and the Minimap2 plugin with default parameters). Coverage analysis showed the CO-1 duplication locus (region 1: positions 1,841,579 to 1,901,680, region 2: 1,910,027 to 1,935,735, DSM 2030 positions) to have a similar read coverage (353.4, 315.7 respectively) as for the rest of the genome (358.9), further confirming that CO-1 SPF-B017 does not bear TnCO-1. Coverage analysis also confirmed CO-1 SPF-B017 to have the same deletion as CO-1(2.5 kb deletion, positions 233,431 to 235,869 in DSM 2030 genome). SNV analysis identified the same mutations bore by CO-1, as well as 3 additional mutations (Table 8).

[0245] Junction-specific sequences: P1 / P2 junction: AAAACAGGGCACTTAAGTGCCCTGTTCAGACTGTTGACAAAATATCGGGA (SEQ ID NO: 24) P3 / P4 junction: AGTATATCTTTTTTATATTATCCATATTGCAAAAGCAAGACAAGTTGGAA (SEQ ID NO: 25)

[0246] Table 8: Identification of mutations (variant frequency > 80%) in the CO-1 SPF-B017 strain. Additional mutations compared to CO-1 are bolded. Silent mutations were filtered out. CO-1 SPF-B017 Locus Tag Product Position Ref. Alt. Mutation Type Freq. TKV_RS00680carbamoyltransferaseHypF 136300 G C Missense (G22A) 97.2%hydroxy-synthaseTKV_RS07415phosphate signalingMissense complex protein PhoU 1459688 C T (D215N)99.3%protein (E349D)corrinoid TKV_RS09640 activation / regeneration1903679 C G Missense 89.4%

[0247] REFERENCES

[0248] Weghoff, M.C., Müller, V., 2016. CO Metabolism in the Thermophilic Acetogen Thermoanaerobacter kivui. Appl. Environ. Microbiol.82, 2312–2319

[0249] Jin, S., Kang, S., Bae, J., Lee, H., Cho, B.-K., 2022. Development of CO gas conversion system using high CO tolerance biocatalyst. Chem. Eng. J.449, 137678

[0250] Kang, S., Song, Y., Jin, S., Shin, J., Bae, J., Kim, D.R., Lee, J.-K., Kim, S.C., Cho, S., Cho, B.-K., 2020. Adaptive Laboratory Evolution of Eubacterium limosum ATCC 8486 on Carbon Monoxide. Front. Microbiol.11, 402

[0251] Pregnon, G., Minton, N.P., Soucaille, P., 2022. Genome Sequence of Eubacterium limosum B2 and Evolution for Growth on a Mineral Medium with Methanol and CO2 as Sole Carbon Sources. Microorganisms 10, 1790

[0252] Grenz, S., Baumann, P.T., Rückert, C., Nebel, B.A., Siebert, D., Schwentner, A., Eikmanns, B.J., Hauer, B., Kalinowski, J., Takors, R., Blombach, B., 2019. Exploiting Hydrogenophaga pseudoflava for aerobic syngas-based production of chemicals. Metab. Eng.55, 220–230

[0253] Zhu, H.-F., Liu, Z.-Y., Zhou, X., Yi, J.-H., Lun, Z.-M., Wang, S.-N., Tang, W.- Z., Li, F.-L., 2020. Energy Conservation and Carbon Flux Distribution During Fermentation of CO or H2 / CO2 by Clostridium ljungdahlii. Front. Microbiol.11, 416

[0254] Lanzillo, F., Ruggiero, G., Raganati, F., Russo, M.E., Marzocchella, A., 2020. Batch Syngas Fermentation by Clostridium carboxidivorans for Production of Acids and Alcohols

[0255] de Lima, L.A., Ingelman, H., Brahmbhatt, K., Reinmets, K., Barry, C., Harris, A., Marcellin, E., Köpke, M., Valgepea, K., 2022. Faster Growth Enhances Low Carbon Fuel and Chemical Production Through Gas Fermentation. Front. Bioeng. Biotechnol.10, 879578

Claims

CLAIMS 1. A method of conditioning a culture of acetogens for acetogenic fermentation of CO gas (“CO feed gas”), thereby to obtain a conditioned culture of acetogens for acetogenic fermentation of CO gas, the method including growing an unconditioned culture of acetogens to be conditioned for acetogenic fermentation of CO feed gas, in a fermentation medium devoid of yeast extract and vitamins for at least three consecutive growth cycles on CO gas (“CO treatment gas”) as a main or sole carbon source, wherein the concentration of CO in the CO treatment gas is incrementally increased over the three growth cycles, thereby producing a conditioned culture of acetogens for acetogenic fermentation of CO feed gas.

2. The method according to claim 1, which includes successively growing the culture of acetogens on CO treatment gas of which the concentration of CO is progressively increased in respective growing cycles, wherein the concentration of CO in the CO treatment gas is incrementally increased from about 30% v / v to 100% v / v.

3. The method according to claim 2, which includes a prior step of growing the culture of acetogens for at least one growth cycle on high CO synthesis gas (“syngas”).

4. The method according to claim 3, which includes a prior step of growing the culture of acetogens for at least one growth cycle on a hydrogen (H2) and carbon dioxide (CO2) gas that is substantially free of CO.

5. The method according to any of claims 1 to 4, which includes –in a first growing stage, growing a culture of acetogens for at least a first growth cycle on a hydrogen (H2) and carbon dioxide (CO2) gas that is substantially free of CO; in a second growing stage, growing the culture of acetogens from the first growing stage for at least a second growth cycle on high CO synthesis gas (“syngas”); and in a third growing stage, successively growing the culture of acetogens from the second growing stage on CO treatment gas, wherein the concentration of CO in the CO treatment gas is progressively increased in at least three growing cycles from about 30% v / v to 100% v / v.

6. The method according to claim 5, wherein the first growing stage comprises at least three successive growth cycles, wherein a fresh gaseous substrate of H2 and CO2 gas is provided after the conclusion of each growth cycle.

7. The method according to claim 5, wherein the second growing stage comprises at least two successive growth cycles, wherein a fresh gaseous substrate of high CO syngas is provided after each growth cycle.

8. The method according to claim 5, wherein the third growing stage comprises successively growing the culture of acetogens from the second growing stage for at least one growth cycle on each of five CO treatment gases of increasing CO concentration respectively, wherein the concentrations of CO in the respective CO treatment gases are 30% v / v, 40% v / v, 50% v / v, 60% v / v and 100% v / v respectively.

9. The method according to claim 5, wherein the unconditioned culture of acetogens that is subjected to conditioning is a wildtype culture of the acetogens.

10. The method according to any of claims 1 to 9, wherein the unconditioned culture of acetogens that is subjected to conditioning is a culture of thermophilic acetogens.

11. The method according to any of claims 1 to 10, wherein the unconditioned culture of acetogens that is subjected to conditioning is a wildtype culture of T. kivui (DSM 2030).

12. An isolated, conditioned strain of an acetogen produced by the method of any of claims 1 to 11.

13. An isolated, conditioned strain of T. kivui adapted to grow on high CO syngas, produced by the method of any of claims 1 to 11, which comprises, relative to a wildtype of T. kivui (DSM 2030) – a duplication of 15,507 bp in the region from 1,917,220 to 1,932,727.

14. The isolated, conditioned strain of T. kivui adapted to growth on high CO syngas according to claim 13, which additionally comprises: at least one SNP mutation, or each of the SNP mutations, selected from at least: cbiQ, cobalt ECF transporter T component at position 341,995; rpoC, DNA-directed RNA polymerase subunit beta’ at positions 1,969,972 and 1,970,146; and dapA, 4-hydroxy-tetrahydrodipicolinate synthase at position 818,980.

15. An isolated, conditioned strain of T. kivui adapted to growth on 100 % CO gas, produced by the method of any of claims 1 to 11, which comprises, in addition to theduplication as described in claim 13, at least one, optionally two, duplications of at least one of the regions between 1,841,579 to 1,901,680 and 1,910,027 to 1,935,735.

16. The isolated, conditioned strain of T. kivui adapted to growth on 100 % CO gas, according to claim 15 which additionally comprises: the SNP mutations as described in claim 14, and relative to a wildtype of T. kivui (DSM 2030), at least one SNP mutation, or each of the SNP mutations, selected from at least: phoU, phosphate signalling complex protein at position 1,459,688; hypF, carbamoyltransferase, at position 136,300; and acsV, corrinoid activation / regeneration protein, at position 1,903,679.

17. The isolated, mutated strain of T. kivui according to claim 15 or 16 wherein duplication / s in the region from 1,841,579 to 1,901,680 and 1,910,027 to 1,935,735 have a size / s of 60,101 bp and 25,708 bp respectively, or a single size of 85,809 bp.

18. An isolated strain of T. kivui adapted to growth on 100 % CO gas, optionally produced by the method of any of claims 1 to 11, which comprises, in addition to duplication / s according to claims 13 and 15 and the SNP mutations according to claims 14 and 16, at least one partial or full deletion, or all of the partial or full deletions, selected from at least, relative to a wildtype of T. kivui (DSM 2030), – GNAT family N-acetyltransferase, partial deletion from position 233,431 to 234,484; DUF881 domain-containing protein, full deletion from position 234,523 to 235,260; and hypothetical protein, partial deletion from position 235,425 to 235,869.

19. A method of acetogenic fermentation of CO gas to be fermented (“CO feed gas”), to produce a fermentation product, the method including growing a conditioned strain of an acetogen according to any of claims 13 to 18 on CO feed gas as main or sole carbon source, thus producing a fermentation product.

20. The method of claim 19, wherein the CO feed gas is an industrial waste gas containing CO gas.

21. The method of claim 19, wherein the CO feed gas is synthesis gas from a gasification process.

22. The method of claim 19, wherein the fermentation product is one or more of acetic acid and a mono- or divalent alcohol or acid.

23. The method of claim 19, wherein the fermentation product is lactic acid.

24. The method of claim 19, wherein the fermentation is performed in a reactor selected from a stirred tank reactor, an airlift bubble column reactor, or a loop fermentation reactor.

25. The method of claim 26 wherein the fermentation is performed continuously and includes continuously feeding fresh CO feed gas into the reactor while continuously withdrawing fermentation product rich fermentation medium from the reactor and recovering fermentation product from the fermentation product rich fermentation medium to produce recovered fermentation product and fermentation product lean, or free, fermentation medium, which is then continuously recycled to the reactor.

26. The method according to claim 25, wherein recovering the fermentation product from fermentation product rich fermentation medium to produce fermentation product lean, or free, fermentation medium is performed using a membrane process, a vaporisation process, or a solvent extraction process.

27. The method according to claim 19, wherein the fermentation of the CO feed gas removes substantially all CO from the CO feed gas by metabolizing substantially all CO content of the CO feed gas.

28. The isolated, conditioned strain of T. kivui of any of claims 13 to 18, wherein the duplication / s are transposable element-induced duplication / s.

29. The isolated, conditioned strain of T. kivui of any of claims 13 to 18, comprising a transposon.

Citation Information

Patent Citations

  • Carbon monoxide and carbon dioxide bioconversion process

    US20200071734A1